超声引导下热消融联合程序性死亡蛋白-1抑制剂治疗结直肠癌肝转移的研究进展

摘要
图/表
参考文献(50)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要结直肠癌（CRC）患者全病程中超半数有肝转移，转移灶多数无法获得根治性切除且易复发，是结直肠癌患者预后差的主要因素。热消融治疗已成为结直肠癌肝转移无法手术患者的替代治疗，不仅可消除局部病灶，亦可增强患者的抗肿瘤免疫反应，但长期而言，不足以预防肿瘤进展。超声因具有实时显像、引导准确、简易便捷等颇多优势，是热消融治疗惯用的引导方式。如今，癌症的免疫疗法新兴崛起，诸如免疫检查点抑制剂（ICIs）等在多种癌症治疗中不断取得突破性进展。许多基础研究发现，热消融联合免疫疗法可以激活患者的免疫抑制状态，为进一步的临床应用提供了充分的理论依据。本文主要阐述结直肠癌肝转移（CRLM）的超声引导下热消融治疗、程序性死亡蛋白-1（PD-1)抑制剂的免疫治疗、以及两者联合应用的研究进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	任建伟周祖邦▲ 马雯娟

关键词 ：结直肠癌肝转移, 热消融, 超声引导, 程序性细胞死亡蛋白1, 免疫疗法

Abstract：More than half of colorectal cancer (CRC) patients have liver metastases in the whole course of the disease.Most of the metastases cannot be radically removed and are prone to recurrence,which is the main factor for the poor prognosis of colorectal cancer patients.Thermal ablation therapy has become an alternative treatment for patients with inoperable colorectal cancer liver metastases.It can not only eliminate local lesions,but also enhance the patients′ anti-tumor immune response,but in the long run,it is not enough to prevent tumor progression.Ultrasound has many advantages such as real-time imaging,accurate guidance,simplicity and convenience, etc.,and is the usual guidance method for thermal ablation therapy.Today,immunotherapy for cancer is emerging,and breakthroughs have been made in the treatment of various cancers,such as immune checkpoint inhibitors (ICIs).Many basic studies have found that thermal ablation combined with immunotherapy can activate the immunosuppressive state of patients,providing a sufficient theoretical basis for further clinical applications.This article mainly describes the research progress of ultrasound-guided thermal ablation therapy of colorectal cancer liver metastases (CRLM),immunotherapy of PD-1 inhibitors,and their combined application.

Key words： Colorectal cancer liver metastasis Thermal ablation Ultrasound guidance programmed death-1 Immunotherapy

收稿日期: 2021-12-28

引用本文:

任建伟周祖邦▲ 马雯娟. 超声引导下热消融联合程序性死亡蛋白-1抑制剂治疗结直肠癌肝转移的研究进展[J]. 中国当代医药, 2022, 29(17): 22-27.
REN Jianwei ZHOU Zubang▲ MA Wenjuan. Research progress of ultrasound-guided thermal ablation combined with programmed death-1 inhibitor in the treatment of colorectal cancer liver metastases. 中国当代医药, 2022, 29(17): 22-27.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I17/22

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	De Greef K，Rolfo C，Russo A，et al.Multisciplinary management of patients with liver metastasis from colorectal cancer[J].World J Gastroenterol，2016，22（32）：7215-7225.
[3]	Jones RP，Poston GJ.Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy[J].Annu Rev Med，2017，68：183-196.
[4]	Gillams A，Goldberg N，Ahmed M，et al.Thermal ablation of colorectal liver metastases：a position paper by an international panel of ablation experts，The Interventional Oncology Sans Frontieres meeting 2013[J].Eur Radiol，2015，25（12）：3438-3454.
[5]	李鑫，梁萍.超声引导下肝癌热消融治疗的现状与进展[J].临床肝胆病杂志，2021，37（03）：510-514.
[6]	Takahashi H，Berber E.Role of thermal ablation in the management of colorectal liver metastasis[J].Hepatobiliary Surg Nutr，2020，9（1）：49-58.
[7]	Mizukoshi E，Yamashita T，Arai K，et al.Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J].Hepatology，2013，57（4）：1448-1457.
[8]	Shi L，Chen L，Wu C，et al.PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor[J].Clin Cancer Res，2016，22（5）：1173-1184.
[9]	Meijerink MR，Puijk RS，van Tilborg A，et al.Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases：A Systematic Review and Meta-Analysis[J].Cardiovasc Intervent Radiol，2018，41（8）：1189-1204.
[10]	Butte JM，Gonen M，Allen PJ，et al.Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer：Potentially Curative Role of Salvage Repeat Resection[J].Ann Surg Oncol，2015，22（8）：2761-2771.
[11]	Zimmermann M，Pedersoli F，Schulze-Hagen M，et al.Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases：mid-term outcome[J].Eur Radiol，2020，30（2）：1221-1227.
[12]	汪鑫，连建安，马红梅，等.肝动脉化疗栓塞联合射频消融与手术切除治疗结直肠癌单发肝转移的疗效比较[J].中国医刊，2020，55（12）：1355-1357.
[22]	Kennedy LB，Salama A.A review of cancer immunotherapy toxicity[J].CA Cancer J Clin，2020，70（2）：86-104.
[23]	Arasanz H，Gato-Canas M，Zuazo M，et al.PD1 signal transduction pathways in T cells[J].Oncotarget，2017，8（31）：51936-51945.
[26]	Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer，2012，12（4）：252-264.
[13]	Chiang J，Cristescu M，Lee MH，et al.Effects of Microwave Ablation on Arterial and Venous Vasculature after Treatment of Hepatocellular Carcinoma[J].Radiology，2016，281（2）：617-624.
[14]	Kallini JR，Gabr A，Abouchaleh N，et al.New Developments in Interventional Oncology：Liver Metastases From Colorectal Cancer[J].Cancer J，2016，22（6）：373-380.
[15]	Gruber -Rouh T，Marko C，Thalhammer A，et al.Current strategies in interventional oncology of colorectal liver metastases[J].Br J Radiol，2016，89（1064）：20151060.
[16]	Gurusamy K，Corrigan N，Croft J，et al.Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases（LAVA）：study protocol for a randomised controlled trial[J].Trials，2018，19（1）：105.
[17]	Takahashi H，Kahramangil B，Kose E，et al.A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases[J].HPB（Oxford），2018，20（12）：1157-1162.
[18]	Correa-Gallego C，Fong Y，Gonen M，et al.A retrospective comparison of microwave ablation vs.radiofrequency ablation for colorectal cancer hepatic metastases[J].Ann Surg Oncol，2014，21（13）：4278-4283.
[19]	Wang J，Liang P，Yu J，et al.Clinical outcome of ultrasoundguided percutaneous microwave ablation on colorectal liver metastases[J].Oncol Lett，2014，8（1）：323-326.
[20]	Ruers T，Van Coevorden F，Punt CJ，et al.Local Treatment of Unresectable Colorectal Liver Metastases：Results of a Randomized Phase ⅡTrial[J].J Natl Cancer Inst，2017，109（9）：djx015.
[21]	Jiang X，Wang J，Deng X，et al.Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape[J].Mol Cancer，2019，18（1）：10.
[24]	Khailaie S，Rowshanravan B，Robert PA，et al.Characterization of CTLA4 Trafficking and Implications for Its Function[J].Biophys J，2018，115（7）：1330-1343.
[25]	Brekke OH，Sandlie I.Therapeutic antibodies for human diseases at the dawn of the twenty-first century[J].Nat Rev Drug Discov，2003，2（1）：52-62.
[27]	Chen XS，Moon JJ，Cheon J.New Opportunities in Cancer Immunotherapy and Theranostics[J].Acc Chem Res，2020，53（12）：2763-2764.
[28]	Seidel JA，Otsuka A，Kabashima K.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer：Mechanisms of Action，Efficacy，and Limitations[J].Front Oncol，2018，8：86.
[29]	Guo ZS.The 2018 Nobel Prize in medicine goes to cancer immunotherapy（editorial for BMC cancer）[J].BMC cancer，2018，18（1）：1086.
[30]	Ishida Y，Agata Y，Shibahara K，et al.Induced expression of PD-1，a novel member of the immunoglobulin gene superfamily，upon programmed cell death[J].EMBO J，1992，11（11）：3887-3895.
[31]	Dai S，Jia R，Zhang X，et al.The PD-1/PD-Ls pathway and autoimmune diseases[J].Cell Immunol，2014，290（1）：72-79.
[32]	Latchman Y，Wood CR，Chernova T，et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol，2001，2（3）：261-268.
[33]	Dong H，Zhu G，Tamada K，et al.B7-H1，a third member of the B7 family，co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med，1999，5（12）：1365-1369.
[34]	Li P，Huang T，Zou Q，et al.FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway[J].J Immunol，2019，202（10）：3065-3075.
[35]	Shindo Y，Yoshimura K，Kuramasu A，et al.Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor[J].Anticancer Res，2015，35（1）：129-136.
[36]	Dong Y，Sun Q，Zhang X.PD-1 and its ligands are important immune checkpoints in cancer[J].Oncotarget，2017，8（2）：2171-2186.
[37]	Pernot S，Terme M，Voron T，et al.Colorectal cancer and immunity：what we know and perspectives[J].World J Gastroenterol，2014，20（14）：3738-3750.
[38]	Fabio G，Monica B，Andrea S，et al.The evolving role of microsatellite instability in colorectal cancer：A review[J].Cancer Treat Rev，2016，51：19-26.
[39]	Malesci A，Laghi L，Bianchi P，et al.Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer[J].Clin Cancer Res，2007，13（13）：3831-3839.
[40]	Editors FTML.Pembrolizumab （Keytruda）for Metastatic Melanoma （online only）[J].Med Lett Drugs Ther，2014，56（1455）：e114-115.
[41]	AndreT，ShiuKK，KimTW，etal.Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer[J].N Engl J Med，2020，383（23）：2207-2218.
[42]	Overman MJ，McDermott R，Leach JL，et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer （Check-Mate 142）：an open-label，multicentre，phase 2 study[J].Lancet Oncol，2017，18（9）：1182-1191.
[46]	石亮荣.射频消融与PD-1 单抗的协同抗肿瘤作用[D].苏州：苏州大学，2015.
[43]	Lenz HJ，Van Cutsem E，Luisa LM，et al.First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer：The Phase ⅡCheckMate 142 Study[J].J Clin Oncol，2022，40（2）：161-170.
[44]	He S，Hu D，Feng H，et al.Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer：a meta-analysis[J].J Comp Eff Res，2020，9（18）：1285-1292.
[45]	Lemdani K，Mignet N，Boudy V，et al.Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma[J].Oncoimmunology，2019，8（3）：1550342.
[47]	Zhu J，Yu M，Chen L，et al.Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer：A pre -clinical study in a murine model[J].Diagn Interv Imaging，2018，99（3）：135-142.
[48]	Chen Z，Shen S，Peng B，et al.Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model[J].Int J Hyperthermia，2009，25（5）：374-382.
[49]	Eranki A，Srinivasan P，Ries M，et al.High-Intensity Focused Ultrasound（HIFU）Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy[J].Clin Cancer Res，2020，26（5）：1152-1161.
[50]	Yang W，Wang W，Liu B，et al.Immunomodulation characteristics by thermal ablation therapy in cancer patients[J].Asia Pac J Clin Oncol，2018，14（5）：e490-e497.